RxDoctor Payments Data

Melissa Delamora

Nurse Practitioner · Reno, NVNPI 1003257775

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,625 of the $20,113 with a category attached, or 82.7%. AbbVie accounts for 87.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $8,306 and has fallen 72.9% since, to $2,248 in 2025. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,113in general payments, 2019–2025

Across 175 payments — averaging $114.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • Abbott$421
  • Saluda Medical Americas, Inc.$325
  • SPR Therapeutics, Inc$254
  • Pfizer$208
  • Vertos Medical, Inc.$168
  • plus $1K from 25 others
$40in research payments, 2019–2025

Across 1 payment — averaging $39.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$40

What the payments were for

  • Speaking & faculty fees$16,62583%
  • Food & beverage$3,47517%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,113 in reported general payments places this provider in the 95th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$85,077
Medicare patients
167
Services billed
2,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen421$10,660
Pregabalin238$6,249
OxycontinOxycodone Hcl17$6,019
Gabapentin297$3,833
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen119$3,131
Oxycodone Hcl155$2,613
Lidocaine14$1,787
Morphine Sulfate ErMorphine Sulfate66$1,206
Fentanyl12$968
Tizanidine Hcl92$847
Cyclobenzaprine Hcl80$605
Duloxetine Hcl59$542
Tramadol Hcl67$489
Ibuprofen42$385
Methocarbamol39$343

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →